Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00759239
• Other study ID #: EMD-06-02
• Status: Completed
• Phase: Phase 4
• First received: September 24, 2008
• Last updated: November 18, 2016
• Start date: September 2008
• Est. completion date: January 2011

Study information

• Verified date: January 2012
• Source: Alcon Research
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Department of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the IOP-lowering efficacy of a combination of Travoprost / Timolol maleate, dosed in the morning or in the evening, in patients with open-angle glaucoma or ocular hypertension, who have an insufficiently controlled IOP (mmHg), and are using prostaglandin analogue monotherapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: January 2011
• Est. primary completion date: January 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion:

• Male or female adult patients over the age of 18 years

• Current treatment with prostaglandin analogue monotherapy, IOP-lowering medication.

• Meet the following IOP entry criteria in at least one treated eye (mean IOP):

• = 19 mmHg

• = 28 mmHg

• The patient is willing and able to sign and date the Informed Consent Form. Patients who wear contact lenses will be able to participate in the study, provided that the contact lenses are removed before instillation of study medication, and that the patient agrees to wait a minimum of 15 minutes, before re-inserting the lenses.

Exclusion:

• Females of childbearing potential (i.e. - those who are not surgically sterilised at least three months prior to the study start, or are not at least one year post-menopausal), who are:

• Currently pregnant

• Have a positive result on a urine pregnancy test at the Eligibility Visit

• Intend to become pregnant during the study period

• Are breast-feeding

• Are not using highly effective birth control measures, for example;

• Hormonal - oral, implanted, or injected contraceptives or;

• Mechanical - spermicide in conjunction with a barrier such a condom or diaphragm or;

• Intra-Uterine Device (IUD)

• Any form of glaucoma other than open-angle glaucoma (with or without a pigment dispersion or pseudo-exfoliation component).

• Current or previous therapy with another investigational agent, within 30 days prior to study entry.

• History of chronic or recurrent severe inflammatory eye disease (e.g., scleritis, uveitis, herpes keratitis), in either eye.

• History of ocular trauma within the past six months in either eye

• History of ocular infection or ocular inflammation within the past three months in either eye.

• History of clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment in either eye.

• History of any other severe ocular pathology (including severe dry eyes), in either eye that would preclude the administration of a topical prostaglandin analogue.

• Intraocular surgery within the past six months as determined by patient history and/or examination in either eye.

• Ocular laser surgery within the past three months as determined by patient history and/or examination in either eye.

• Any abnormality preventing reliable applanation tonometry of either eye.

• Angle grade less than Grade 2 in either eye, as measured by gonioscopy (extreme narrow angle with complete or partial closure), assessed within the previous 12 months.

• Cup/disc ratio greater than 0.80 in either eye, assessed within the previous six months.

• Severe central visual field loss in either eye, defined as a sensitivity of = 10 bB in at least two of the four visual field test points, closest to the point of fixation, assessed within the previous six months.

• Unable to safely discontinue all IOP lowering medication, for a minimum period of 28 days prior to Baseline Visit.

• Unable to safely discontinue all glucocorticoid medications administered by any route. Before the Eligibility Visit, patients must have performed a Wash Out of at least four weeks for any intermittent glucocorticoid medications and must be able to remain off these medications for the duration of the study.

• Use of any additional topical or systemic ocular hyposensitive medication during the study.

• History of bronchial asthma, or severe chronic obstructive pulmonary disease that would preclude the safe administration of a topical beta-blocker.

• Less than 30 days stable dosing regimen before the Screening Visit of any non-glaucoma medications or substances administered by any route and used on a chronic basis that may affect IOP. These may include, but are not limited to the following:

• Sympathomimetic agents

• Antimuscarinic agents

• Antihistamines

• Phenothiazines

• Tricyclic antidepressants

• Beta-antagonist blocking agents

• Alpha agonists

• Alpha-adrenergic blocking agents

• Calcium channel blockers

• Angiotensin converting enzyme inhibitors

• Cardiac gylcosides

• History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Open-Angle
• Hypertension
• Ocular Hypertension
• Open-angle Glaucoma

Intervention

Drug:
• Travoprost 0.004% / Timolol maleate 0.5%
Solution, morning dosing
• Travoprost 0.004% / Timolol maleate 0.5%
Solution, evening dosing

Locations

Country	Name	City	State
United Kingdom	Western Eye Hospital	London

Sponsors (1)

Lead Sponsor	Collaborator
Alcon Research

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction in intraocular pressure		week 4, week 12	No
Secondary	Adverse events		Week 4, week 12	Yes

External Links

•   Results on European Database